Arrowhead Pharmaceuticals could notch more gains as the biotechnology firm prepares to release data tied to clinical trials for its treatment for a very common medical condition, according to Morgan Stanley. The investment bank upgraded the pharma stock to overweight from equal weight. It also hiked its price target on shares to $100 from $78, implying 44.4% upside from Monday's close. Arrowhead h...
Arrowhead Pharmaceuticals could notch more gains as the biotechnology firm prepares to release data tied to clinical trials for its treatment for a very common medical condition, according to Morgan Stanley. The investment bank upgraded the pharma stock to overweight from equal weight. It also hiked its price target on shares to $100 from $78, implying 44.4% upside from Monday's close. Arrowhead has already been on fire of late. The stock is up more than 473% over the past year. However, analyst Michael Ulz thinks shares have even more room to run. ARWR 1Y mountain ARWR 1-yr chart "We expect momentum to continue ahead of [phase three clinical trial] data [for Plozasiran] in 3Q26, where we expect positive data to unlock a multibillion-dollar opportunity that remains underappreciated," analyst Ulz said in a note to clients. "This combined with pipeline optionality contributes to a favorable outlook. Arrowhead Pharmaceuticals is expected to release data from the third phase of studies on its investigational RNA interference therapeutic Plozasiran in the third quarter of 2026 — a move that could boost its stock, according to Morgan Stanley. The medication is designed to treat patients with severe hypertriglyceridemia, a condition that affects one-in-five adults in the U.S., according to non-profit medical center Cleveland Clinic. "Data from studies of plozasiran (Redemplo) in severe hypertriglyceridemia are "expected to drive continued momentum," Ulz wrote. "Based on prior data and a similarly designed study with a comparable patient population … we expect positive results." "While enthusiasm around SHTG has already driven notable share appreciation, we see opportunity for further upside supported by our higher sales expectations," Ulz wrote. Morgan Stanley's call falls in line with consensus on Wall Street. Of the 13 analysts covering the stock, 10 have a buy or strong buy rating on shares, LSEG data shows.
Core Scientific ( CORZ ) wholly-owned subsidiary, Core Scientific Finance I LLC, plans to offer $3.3B of senior secured notes due 2031 in a private offering . The issuer plans to use the net proceeds from the offering to fund a debt service reserve account, and the remaining proceeds to make a distribution to Core Scientific. Core Scientific ( CORZ ) intends to use a portion of the net proceeds it...
Core Scientific ( CORZ ) wholly-owned subsidiary, Core Scientific Finance I LLC, plans to offer $3.3B of senior secured notes due 2031 in a private offering . The issuer plans to use the net proceeds from the offering to fund a debt service reserve account, and the remaining proceeds to make a distribution to Core Scientific. Core Scientific ( CORZ ) intends to use a portion of the net proceeds it receives to repay in full its outstanding delayed draw term loans under its previously announced 364-day credit facility, including accrued interest thereon and fees and expenses in connection therewith. CORZ shares rose +4.6% premarket. More on Core Scientific Core Scientific Hints At Outsized FY2026/FY2027 Prospects - Maintain Buy Core Scientific, Inc. 2025 Q4 - Results - Earnings Call Presentation Core Scientific, Inc. (CORZ) Q4 2025 Earnings Call Transcript Core Scientific boosts strategic financing facility to $1B Core Scientific secures strategic financing with Morgan Stanley for up to $1B
Shares of AXT ( AXTI ) fell nearly 12% at $69 in premarket trading on Tuesday after the semiconductor materials maker priced a $550M worth public offering of common stock at a discount. The company said it will sell 8,560,311 shares at $64.25 each, making proceeds of about $550M before fees and expenses. AXT's closing price on Monday was $78.76. AXT also granted underwriters a 30-day option to pur...
Shares of AXT ( AXTI ) fell nearly 12% at $69 in premarket trading on Tuesday after the semiconductor materials maker priced a $550M worth public offering of common stock at a discount. The company said it will sell 8,560,311 shares at $64.25 each, making proceeds of about $550M before fees and expenses. AXT's closing price on Monday was $78.76. AXT also granted underwriters a 30-day option to purchase up to an additional 1,284,046 shares. If fully exercised, total gross proceeds would rise to about $632.5M.The company said it plans to use the proceeds primarily to support subsidiary Beijing Tongmei Xtal Technology as it expands capacity for indium phosphide substrate production for export markets and for research and development, working capital, and other corporate purposes. Northland is acting as sole bookrunner on the deal, with Needham, B. Riley, Craig-Hallum Capital, and Wedbush Securities serving as co-managers.The offering is expected to close on April 22. More on AXT AXT: A $3 Billion Valuation For A $88 Million Revenue Reality Check AXT: I Was Bullish At $2, But It's Time To Sell At $70 AXT: A Promising Semiconductor Materials Story Trading Far Ahead Of Its Revenue Base Biggest stock movers Tuesday: AMZN, LCID, UNH, and more AXT plans public stock offering; shares down
Northrop Grumman (NOC) delivered earnings and revenue surprises of +0.99% and +1.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Northrop Grumman (NOC) delivered earnings and revenue surprises of +0.99% and +1.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Tractor Supply (TSCO) delivered earnings and revenue surprises of -10.15% and -1.48%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Tractor Supply (TSCO) delivered earnings and revenue surprises of -10.15% and -1.48%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Genuine Parts (GPC) delivered earnings and revenue surprises of -1.94% and +1.55%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Genuine Parts (GPC) delivered earnings and revenue surprises of -1.94% and +1.55%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Adversaries injected malicious prompts into legitimate AI tools at more than 90 organizations in 2025, stealing credentials and cryptocurrency. Every one of those compromised tools could read data, and none of them could rewrite a firewall rule. The autonomous SOC agents shipping now can. That escalation, from compromised tools that read data to autonomous agents that rewrite infrastructure, has n...
Adversaries injected malicious prompts into legitimate AI tools at more than 90 organizations in 2025, stealing credentials and cryptocurrency. Every one of those compromised tools could read data, and none of them could rewrite a firewall rule. The autonomous SOC agents shipping now can. That escalation, from compromised tools that read data to autonomous agents that rewrite infrastructure, has not been exploited in production at scale yet. But the architectural conditions for it are shipping faster than the governance designed to prevent it. A compromised SOC agent can rewrite your firewall rules, modify IAM policies, and quarantine endpoints, all with its own privileged credentials, all through approved API calls that EDR classifies as authorized activity. The adversary never touches the network. The agent does it for them. Cisco announced AgenticOps for Security in February, with autonomous firewall remediation and PCI-DSS compliance capabilities. Ivanti launched Continuous Compliance and the Neurons AI self-service agent last week, with policy enforcement, approval gates and data context validation built into the platform at launch — a design distinction that matters because the OWASP Agentic Top 10 documents what happens when those controls are absent. "Adversaries exploited legitimate AI tools by injecting malicious prompts that generated unauthorized commands. As innovation accelerates, exploitation follows," CrowdStrike CEO George Kurtz said when releasing the 2026 Global Threat Report. "AI is compressing the time between intent and execution while turning enterprise AI systems into targets," added Adam Meyers, head of counter-adversary operations at CrowdStrike. State-sponsored use of AI in offensive operations surged 89% over the prior year. The broader attack surface is expanding in parallel. Malicious MCP server clones have already intercepted sensitive data in AI workflows by impersonating trusted services. The U.K. National Cyber Security Centre warne...
Dividend stocks are back in favor again. That means it's time to consider dividend ETFs you may have ignored in recent years. The Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) is the top-performing U.S. dividend ETF so far in 2026. Its strategy of requiring at least 10 consecutive years of dividend payments, strong balance sheet fundamentals, and above-average yields produces a "best of the best...
Dividend stocks are back in favor again. That means it's time to consider dividend ETFs you may have ignored in recent years. The Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) is the top-performing U.S. dividend ETF so far in 2026. Its strategy of requiring at least 10 consecutive years of dividend payments, strong balance sheet fundamentals, and above-average yields produces a "best of the best" stock portfolio that has delivered for shareholders. That strategy aligns with what investors are looking for right now. It may even be a better investment than the Vanguard S&P 500 ETF (NYSEMKT: VOO) at the moment. Continue reading
watch now VIDEO 3:56 03:56 How Fed Chair nominee Kevin Warsh made his fortune The Fed What you need to know Federal Reserve chair nominee Kevin Warsh will face the Senate Banking committee at 10 a.m. on Tuesday for a confirmation hearing. Warsh would be the wealthiest Fed chair if confirmed, he disclosed to the committee. The pick of President Donald Trump , Warsh would replace Jerome Powell as Fe...
watch now VIDEO 3:56 03:56 How Fed Chair nominee Kevin Warsh made his fortune The Fed What you need to know Federal Reserve chair nominee Kevin Warsh will face the Senate Banking committee at 10 a.m. on Tuesday for a confirmation hearing. Warsh would be the wealthiest Fed chair if confirmed, he disclosed to the committee. The pick of President Donald Trump , Warsh would replace Jerome Powell as Fed chair. Kevin Warsh , the 56-year-old former Federal Reserve governor, is taking the hot seat at 10 a.m. for his Senate Banking Committee confirmation hearing. Warsh will field questions on a wide range of issues, ranging from his views on monetary policy to his sprawling and complex personal finances . He would become the wealthiest Fed chair if confirmed. Some of the most important exchanges for his candidacy may center on how he views the boundaries between the Fed's decision-making and politics . Questions about the Fed's long-cherished independence have dominated the discourse surrounding the central bank during Trump's second term. President Donald Trump, who originally nominated Jerome Powell for Fed chair during his first term in 2017, has waged a long-term campaign to try to browbeat the central bank leader into hastily slashing interest rates . Powell in recent months has been embroiled in a Department of Justice criminal probe after refusing to acquiesce to Trump's demands. Warsh, in his prepared statement to the Banking Committee, gave a qualified endorsement of Fed independence — but noted he doesn't believe that dynamic is endangered when the central bank's actions are questioned by elected leaders. CNBC's reporters are covering the hearing, live on air and online from our bureaus in Washington and Englewood Cliffs, New Jersey.